AZ Takes Time To Answer EU Queries On Broadening Brilique Indication
CHMP Opinion On Extending Use In High-Risk CAD Patients Due In H2
You may also be interested in...
Keeping Track: Tecentriq, Cyramza Celebrate ASCO With New Indications; Brilinta Moves Earlier In Coronary Artery Disease
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.
Farxiga CKD Trial Stopped Early For Efficacy, Giving The SGLT2 Inhibitor An Edge
A Phase III trial testing dapagliflozin in chronic kidney disease patients with and without diabetes was stopped early following a recommendation from an independent data monitoring committee.